tradingkey.logo

BRIEF-Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, And Tolerability Study Of SP-26 For Chronic Pain And Fibromyalgia

ReutersFeb 11, 2025 1:02 PM

- Silo Pharma SILO.O:

  • SILO PHARMA ANNOUNCES POSITIVE INITIAL PHARMACOKINETIC, SAFETY, AND TOLERABILITY STUDY OF SP-26 FOR CHRONIC PAIN AND FIBROMYALGIA

  • SILO PHARMA INC - NO SERIOUS SIDE EFFECTS OBSERVED IN SP-26 STUDY

  • SILO PHARMA INC - FINAL SAFETY AND ABSORPTION DATA EXPECTED IN MARCH 2025

Source text: ID:nGNX7qL6FT

Further company coverage: SILO.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI